AstraZeneca (NYSE: AZN) today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.
The ONSET/OFFSET data showed that treatment with ticagrelor (BRILINTA(TM)) achieved a more rapid onset of antiplatelet effect (41% IPA vs. 8% at 30 minutes; P<0.0001), greater inhibition of platelet aggregation (IPA) that was sustained during maintenance phase of treatment (IPA; P<0.0001 at all times) and faster offset IPA compared to clopidogrel, in patients with stable coronary artery disease (CAD) on aspirin therapy.
Platelets initiate the formation of blood clots by sticking together (clumping or aggregating), a process called platelet aggregation. Inhibition of platelet aggregation (IPA) is the prevention of clumping of platelets in the blood, which reduces the risk of clot formation and subsequent thrombotic events.
These results were achieved using ticagrelor 180 mg loading dose followed by 90 mg twice daily, as studied in PLATO (A Study of Platelet Inhibition and Patient Outcomes), compared to clopidogrel 600 mg loading dose followed by 75 mg once daily dose.
Key findings:
- Greater IPA occurred with ticagrelor compared to clopidogrel at time points of 0.5, 1, 2, 4, 8 and 24 hours after patients received initial treatment dose and at 6 weeks (P<0.0001 for all)
- At 2 hours after patients received initial treatment dose a greater proportion of patients achieved >50% IPA (98% vs. 31%, P<0.0001) and >70% IPA (90% vs. 16%, P<0.0001) in the ticagrelor versus clopidogrel group, respectively.
- A faster offset of IPA occurred with ticagrelor than clopidogrel (4 to 72 hour slope (IPA (%)/hour): -1.037 vs. -0.482, P<0.0001). At 24 h after last treatment dose, mean IPA was 58% for ticagrelor vs. 52% for clopidogrel>
- IPA for ticagrelor on day 3 after the last dose was comparable to clopidogrel at day 5;
In the Phase II RESPOND study, the antiplatelet effect of ticagrelor on both clopidogrel responders and non-responders were evaluated in 98 patients with stable coronary artery disease.
Among patients identified as clopidogrel responders, switching from clopidogrel to ticagrelor resulted in a mean IPA increase of 26% and switching from ticagrelor to clopidogrel resulted in a mean IPA decrease of 24%, suggesting that patients can be switched from clopidogrel to ticagrelor without interruption of antiplatelet effect.